Lenvatinib Plus Pembrolizumab in Patients With Advanced Endometrial Cancer
Lenvatinib Plus Pembrolizumab in Patients With Advanced Endometrial Cancer is a paper indexed in ScholarIQ from OpenAlex.
How many citations does Lenvatinib Plus Pembrolizumab in Patients With Advanced Endometrial Cancer have?
Lenvatinib Plus Pembrolizumab in Patients With Advanced Endometrial Cancer has 525 citations in the OpenAlex counts ScholarIQ stores.
When was Lenvatinib Plus Pembrolizumab in Patients With Advanced Endometrial Cancer published?
Lenvatinib Plus Pembrolizumab in Patients With Advanced Endometrial Cancer has 2020 year in the ScholarIQ index.
What is the open-access status of Lenvatinib Plus Pembrolizumab in Patients With Advanced Endometrial Cancer?
Lenvatinib Plus Pembrolizumab in Patients With Advanced Endometrial Cancer has hybrid oa status in the ScholarIQ index.
What is the DOI of Lenvatinib Plus Pembrolizumab in Patients With Advanced Endometrial Cancer?
The DOI for Lenvatinib Plus Pembrolizumab in Patients With Advanced Endometrial Cancer is on the source record.
What is the PMID of Lenvatinib Plus Pembrolizumab in Patients With Advanced Endometrial Cancer?
The PMID for Lenvatinib Plus Pembrolizumab in Patients With Advanced Endometrial Cancer is on the source record.
What is the OpenAlex record for Lenvatinib Plus Pembrolizumab in Patients With Advanced Endometrial Cancer?
The OpenAlex for Lenvatinib Plus Pembrolizumab in Patients With Advanced Endometrial Cancer is on the source record.